Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.

Mural Oncology plc

We know that drug development is both an art and a science.

The work we do is incredibly technical, intentional, and specific, but there is an art to it - because we must leave room for creativity, innovation and spontaneity. Murals are paintings that transform overlooked or unused spaces - creating something impactful and meaningful. There remains many overlooked opportunities in cancer drug development. This is what inspires us.

Our mission is simple, to create novel immunotherapies that can change patients’ lives so they can get back to what matters most - living.

Mural Oncology is leveraging its industry-leading protein engineering platform to revolutionize cytokine-based immunotherapies for the treatment of cancer. 

Immunotherapies have been transformative for some people living with cancer, but unfortunately many patients still do not benefit - either because they are ineligible for treatment or they do not respond well to current therapies.  

We leverage our expertise in cytokine biology, immune cell modulation and our protein engineering capabilities to develop first and novel immunotherapies. Our goal is to deliver meaningful, clinical benefit across a wide range of cancers, including tumor types where immunotherapies have previously not been effective.

Mural Oncology is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers. (NASDAQ: MURA)


Mural Oncology

Today marks a notable milestone as Mural Oncology officially launches as an independent, publicly traded, clinical-stage immuno-oncology company. Tomorrow, find us on Nasdaq as $MURA.

Mural's dedication to advancing our pipeline of novel engineered cytokine immunotherapies with our lead candidate, nemvaleukin alfa, is backed by a strong foundation of $275 million in committed funding, and a clear vision to reimagine cytokine-based immunotherapies for the treatment of cancer. 

Our mission is simple: to create novel immunotherapies that can change patients’ lives so they can get back to what matters most - living. Learn more:  https://bit.ly/47AUnhN #oncology #biotechnology #innovation #immunooncology #Nasdaq

	Sep '22	Dec '22	Mar '23	Jun '23	Sep '23	Dec '23	Mar '24	Sep '24
net income	-50.64M -	-48.58M 4.07%	-46.47M 4.35%	-50.16M 7.96%	-51.28M 2.22%	-59.54M 16.10%	-30.92M 48.07%	-31.76M -
depreciation and amortization	372K -	497K 33.60%	530K 6.64%	645K 21.70%	779K 20.78%	613K 21.31%	846K 38.01%	898K -
deferred income tax
stock based compensation	3.48M -	3.20M 8.11%	2.75M 13.89%	3.14M 14.09%	2.98M 5.03%	15.23M 410.63%	2.20M 85.56%	1.03M -
change in working capital	9.49M -	7.00M 26.25%	-12.55M 279.28%	1.06M 108.46%	-2.95M 378.06%	966K 132.71%	-9.47M 1,079.92%	6.98M -
accounts receivables							3.65M -	-4.54M -
inventory
accounts payables								4.33M -
other working capital			-12.55M -				-13.12M -	7.19M -
other non cash items			3.81M -				238K -	-7.23M -
net cash provided by operating activities	-37.30M -	-37.89M 1.57%	-55.74M 47.12%	-45.32M 18.70%	-50.47M 11.38%	-42.73M 15.35%	-37.34M 12.61%	-30.08M -
investments in property plant and equipment	-2.70M -	-143K 94.70%	-398K 178.32%	-710K 78.39%	-1.17M 64.23%	-1.18M 1.03%	-55K 95.33%	-14K -
acquisitions net
purchases of investments							-124.48M -	-23.67M -
sales maturities of investments								43M -
other investing activites
net cash used for investing activites	-2.70M -	-143K 94.70%	-398K 178.32%	-710K 78.39%	-1.17M 64.23%	-1.18M 1.03%	-124.54M 10,472.16%	19.31M -
debt repayment
common stock issued
common stock repurchased
dividends paid
other financing activites	39.99M -	38.03M 4.92%	56.13M 47.61%	46.03M 18.01%	51.64M 12.19%	315.01M 510.05%		196K -
net cash used provided by financing activities	39.99M -	38.03M 4.92%	56.13M 47.61%	46.03M 18.01%	51.64M 12.19%	315.01M 510.05%		196K -
effect of forex changes on cash
net change in cash						271.11M -	-163.59M 160.34%	-8.60M -
cash at beginning of period							270.85M -	121.59M -
cash at end of period						271.11M -	107.26M 60.44%	112.99M -
operating cash flow	-37.30M -	-37.89M 1.57%	-55.74M 47.12%	-45.32M 18.70%	-50.47M 11.38%	-42.73M 15.35%	-37.34M 12.61%	-30.08M -
capital expenditure	-2.70M -	-143K 94.70%	-398K 178.32%	-710K 78.39%	-1.17M 64.23%	-1.18M 1.03%	-55K 95.33%	-14K -
free cash flow	-39.99M -	-38.03M 4.92%	-56.13M 47.61%	-46.03M 18.01%	-51.64M 12.19%	-43.90M 14.98%	-37.39M 14.83%	-30.09M -

MURA

COM:MURALONCOLOGY

Mural Oncology plc

Last Close

3.37

22/11 21:00

Market Cap

51.45M

Beta: -

Volume Today

35.85K

Avg: -

Preview